PubMed Health⌕ Search

Biomedical subjects

V P Kozachenko

Publications and source records attributed to V P Kozachenko.

At least 19 recordsLinked to original sources
PubMed1998

[Clinical evaluation of different methods of treatment in patients with endometrial stromal sarcoma of the uterus].

The data on treatment of 50 patients with endometrial stromal sarcoma (Ess) are discussed. Mean age-46.5 years. The group included 28 patients with stage I tumor, 7-stage II, 8-stage III and 7-stage IV. The end results of surgical, combined and complex treatment were followed up in 45 cases. Surgery was given to 24 and combined and complex therapy-to 21 patients. Five- and ten-year survival was 55.6 and 26.7, respectively, whatever mode of therapy and stage.

Adult↗
PubMed1998

[Surgical treatment of patients with borderline serous tumors of the ovary].

The paper deals with the data on treatment of 63 patients with serous borderline tumors of the ovary (SBTO). Mean age was 40.2 years. The study included 30 patients (47.6%) with stage IA tumor, 15 (23.8%)--IB, 4 (6.3%)--II and 14 (22.2%)--stage III. Relapse frequency was 14.3%, irrespective of stage and method of therapy. Surgery was given to 18 patients (28.6%), combined therapy--by 45 (71.4%). Recurrent tumor was recorded after surgery in 2 (3.2%) and in 7 (14.8%) after combined therapy. Generally, surgery is the main treatment received by patients with SBTO. Adjuvant chemotherapy was not followed by decrease in relapse rates.

Adolescent↗
PubMed1998

[Role of surgical interventions in the treatment of patients with trophoblastic tumor resistant to chemotherapy].

A retrospective evaluation of 85 case histories of chemotherapy-resistant trophoblastic disease treated at the Center's clinic (1975-1996) was carried out. Both therapy efficacy and survival rates were lower in patients operated on prior to chemotherapy and during medication. However, excision of resistant foci of trophoblastic tumor contributed to the effectiveness of chemotherapy.

Adult↗
PubMed1993

[The characteristics of prostaglandin E synthesis in epithelial ovarian tumors].

Comparative investigation of prostaglandin E (PGE) levels in primary malignant and benign epithelial tumors, metastases, and normal tissue of the ovaries has revealed more significant variations in PGE levels in malignant tumors than in benign ones. PGE content was reliably higher in adenocarcinomas as against benign tumors and normal ovarian tissue. No noticeable differences in PGE levels of benign tumors and normal tissue were revealed. The possibility of using arachidonic acid cyclooxygenase metabolism blockers in therapy of ovarian carcinoma, besides the common methods of treatment, is discussed.

Adult↗
PubMed1993

[The immunocorrective therapy of cervix uteri diseases].

Analyzes the results of comprehensive clinical and immunologic examinations of women with inflammatory and tumorous diseases of the cervix uteri. Demonstrates a reduction of the immunologic reactions in such diseases and in traditional antibiotic therapy thereof. Presents methods of immunocorrective therapy with vitamin E, thymactin, and sodium nucleinate to be carried out on an inpatient basis.

Adjuvants, Immunologic↗
PubMed1992

Influence of metastases on the prognosis of adenocarcinoma of uterine cervix.

95 cases of adenocarcinoma of the uterine cervix were analysed for the influence of metastasis on the prognosis. When there was penetration of cervical stroma, < 10 mm or > 10 mm, spread of the tumour to the uterine corpus, metastasis in the ovaries and no detection of metastasis in patients the differences in survival rates were not statistically significant. Local spread of adenocarcinoma to the uterine corpus, penetration of cervical stroma > 10 mm and metastasis to ovaries may not adversely influence the patients survival.

Adenocarcinoma↗
PubMed1987

[Clinical importance of determining steroid hormone receptors in endometrial adenocarcinomas].

Estradiol receptor (ER) and progesterone receptor (PR) levels were measured in 216 endometrial adenocarcinomas. Tumors containing more than 10 fmol/mg protein (for ER) and 20 fmol/mg (for PR) were considered receptor-positive. Tumors were both ER- and PR-positive in 75%. In stage I and II tumors, ER and PR levels were significantly higher than in stages III and IV. A similar relationship was established for minor (not deeper than 0.5 cm) and considerable involvement (deeper than 0.5 cm). There was an inverse correlation between ER and PR levels and ER- and PR-positive tumors incidence, on the one hand, and anaplasia, on the other. Adjuvant progestin therapy proved ineffective in tumors with a PR level under 100 mol/mg protein.

Adenocarcinoma↗
PubMed1987

[Role of pathological dedifferentiation in the level of exfoliation of elements of the multilayer epithelium of the uterine cervix].

In cervical dysplasias, dissociation of intercellular junctions occurs to a degree that depends directly on the severity of the dysplastic process which involves the entire epithelium from the basement membrane to the surface layer. The present cytologic studies have demonstrated that as the severity of dysplasia increases, smears taken from exfoliative cells of the stratified squamous epithelium show proportional decreases in the number of cells from the upper epithelial layers and increases in that of cells from the lower levels. The findings obtained indicate that morphologic characterization of exfoliative cellular material may help in the early cytologic diagnosis of cervical disorders.

Adult↗
PubMed1985

[Monoclonal antibodies in the radioimmunological diagnosis of malignant tumors of the gastrointestinal tract and ovaries].

The report deals with the clinical significance of application of two procedures of radioimmunologic assay of levels of monoclonal CA-19-9 and CA-125 antigens in diagnosing gastrointestinal and ovarian malignancies. The CA-19-9 antigen test appeared to be ineffective at the early stages of development of malignant tumors of the stomach, rectum and colon. The level of the antigen showed an increase in 37% of cases of hepatic metastases only. However, the test may be instrumental in differentiating between inflammatory processes and malignancies in the pancreatohepatoduodenal area. CA-125 antigen serves as a discriminating marker for tumor involvement of the ovaries. However, its specificity in differentiating between benign and malignant tumors of this organ is under 63%.

Antibodies, Monoclonal↗